File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers

TitleTiming of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers
Authors
Issue Date2014
PublisherSpringer US. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6806
Citation
Breast Cancer Research and Treatment, 2014, v. 143 n. 3, p. 579-86 How to Cite?
AbstractIt is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case–control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20–1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99–1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14–1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03–1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79–1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.
Persistent Identifierhttp://hdl.handle.net/10722/207306

 

DC FieldValueLanguage
dc.contributor.authorKotsopoulos, Jen_US
dc.contributor.authorLubinski, Jen_US
dc.contributor.authorMoller, Pen_US
dc.contributor.authorLynch, HTen_US
dc.contributor.authorSinger, CFen_US
dc.contributor.authorEng, Cen_US
dc.contributor.authorNeuhausen, SLen_US
dc.contributor.authorKarlan, Ben_US
dc.contributor.authorKim-Sing, Cen_US
dc.contributor.authorHuzarski, Ten_US
dc.contributor.authorGronwald, Jen_US
dc.contributor.authorMaCuaig, Jen_US
dc.contributor.authorSenter, Len_US
dc.contributor.authorTung, Nen_US
dc.contributor.authorGhadirian, Pen_US
dc.contributor.authorEisen, Aen_US
dc.contributor.authorGilchrist, Den_US
dc.contributor.authorKwong, Aen_US
dc.date.accessioned2014-12-19T10:20:43Z-
dc.date.available2014-12-19T10:20:43Z-
dc.date.issued2014en_US
dc.identifier.citationBreast Cancer Research and Treatment, 2014, v. 143 n. 3, p. 579-86en_US
dc.identifier.urihttp://hdl.handle.net/10722/207306-
dc.description.abstractIt is not clear if early oral contraceptive use increases the risk of breast cancer among young women with a breast cancer susceptibility gene 1 (BRCA1) mutation. Given the benefit of oral contraceptives for the prevention of ovarian cancer, estimating age-specific risk ratios for oral contraceptive use and breast cancer is important. We conducted a case–control study of 2,492 matched pairs of women with a deleterious BRCA1 mutation. Breast cancer cases and unaffected controls were matched on year of birth and country of residence. Detailed information about oral contraceptive use was collected from a routinely administered questionnaire. Conditional logistic regression was used to estimate the odds ratios (OR) and 95 % confidence intervals (CI) for the association between oral contraceptive and breast cancer, by age at first use and by age at diagnosis. Among BRCA1 mutation carriers, oral contraceptive use was significantly associated with an increased risk of breast cancer for women who started the pill prior to age 20 (OR 1.45; 95 % CI 1.20–1.75; P = 0.0001) and possibly between ages 20 and 25 as well (OR 1.19; 95 % CI 0.99–1.42; P = 0.06). The effect was limited to breast cancers diagnosed before age 40 (OR 1.40; 95 % CI 1.14–1.70; P = 0.001); the risk of early-onset breast cancer increased by 11 % with each additional year of pill use when initiated prior to age 20 (OR 1.11; 95 % CI 1.03–1.20; P = 0.008). There was no observed increase for women diagnosed at or after the age of 40 (OR 0.97; 95 % CI 0.79–1.20; P = 0.81). Oral contraceptive use before age 25 increases the risk of early-onset breast cancer among women with a BRCA1 mutation and the risk increases with duration of use. Caution should be taken when advising women with a BRCA1 mutation to take an oral contraceptive prior to age 25.en_US
dc.languageengen_US
dc.publisherSpringer US. The Journal's web site is located at http://springerlink.metapress.com/openurl.asp?genre=journal&issn=0167-6806en_US
dc.relation.ispartofBreast Cancer Research and Treatmenten_US
dc.titleTiming of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriersen_US
dc.typeArticleen_US
dc.identifier.emailKwong, A: avakwong@hkucc.hku.hken_US
dc.identifier.authorityKwong, A=rp01734en_US
dc.identifier.doi10.1007/s10549-013-2823-4en_US
dc.identifier.hkuros241717en_US
dc.identifier.volume143en_US
dc.identifier.issue3en_US
dc.identifier.spage579en_US
dc.identifier.epage86en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats